Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study

INTRODUCTION: Since hematopoietic stem cell transplant (HSCT) is an important therapy for malignant and non-malignant pediatric diseases, improving transplant-related mortality remains a challenge. Currently, rituximab, a monoclonal antibody of anti-CD20, is widely used for several post-HSCT complic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Yongsheng, Chen, Libai, Luo, Tingting, Xie, Danfeng, Cao, Wei, Liu, Xuan, Liu, Qiujun, Xiao, Yuhua, Wu, Cuiling, Wen, Jianyun, Li, Juan, Meng, Jiangnan, Wu, Xuedong, Feng, Xiaoqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505124/
https://www.ncbi.nlm.nih.gov/pubmed/37470925
http://dx.doi.org/10.1007/s40121-023-00841-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505124/
https://www.ncbi.nlm.nih.gov/pubmed/37470925
http://dx.doi.org/10.1007/s40121-023-00841-x

Ejemplares similares